^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    C-13-60

    i
    Other names: C-13-60, CEA-targeted CAR-T therapy
    Associations

    News

    Trials
    Company:
    Chongqing Precision Biotech
    Drug class:
    CEA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    6ms
    Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study. (PubMed, Cytotherapy)
    Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • PSCA (Prostate Stem Cell Antigen 2)
    |
    C-13-60
    6ms
    Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    cyclophosphamide • C-13-60
    6ms
    Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • Metastases
    |
    CEACAM5 positive
    |
    cyclophosphamide • C-13-60
    8ms
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • CAR T-Cell Therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • ALK positive • EGFR T790M • ALK fusion • EGFR positive • CEACAM5 positive
    |
    cyclophosphamide • C-13-60
    9ms
    Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • Metastases
    |
    IL6 (Interleukin 6) • CD70 (CD70 Molecule)
    |
    CEACAM5 positive
    |
    cyclophosphamide • C-13-60
    1year
    Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6)
    |
    CEACAM5 positive
    |
    C-13-60